Shu-Ru Kuo

Title: Innovations of Shu-Ru Kuo

Introduction

Shu-Ru Kuo is an accomplished inventor based in Temple, Texas. He is known for his significant contributions to the field of immunology, particularly in the development of bispecific antibodies. His innovative work aims to enhance targeted therapies for cancer treatment.

Latest Patents

Shu-Ru Kuo holds a patent for a bispecific scFv immunofusion (BIf). This invention is designed to bind to cell surface molecules on target cells, such as cancer cells, and immune effector cells, like cytotoxic T lymphocytes. The result is a targeted approach to killing cancer cells. The BIf is characterized as a polypeptide that includes a first target binding domain for cancer cells, a second effector binding domain for immunologic effectors, and an immunoglobulin constant region linker that connects the two binding domains.

Career Highlights

Throughout his career, Shu-Ru Kuo has worked with notable organizations, including Scott & White Healthcare and Aptevo Research and Development LLC. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Shu-Ru Kuo has collaborated with Jen-Sing Liu, a talented woman in the field. Their partnership has likely fostered innovative ideas and advancements in their research endeavors.

Conclusion

Shu-Ru Kuo's work in developing bispecific antibodies represents a significant advancement in cancer treatment. His innovative approach has the potential to improve therapeutic outcomes for patients.